SCHEMBL141818

SCHEMBL141818

Cc1cccc(CS(=O)(=O)c2ccc3c(c2)/C(=C/c2[nH]c(C)c(C(=O)N4CCN(C)CC4)c2C)C(=O)N3)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.67
FGFR1 P11362 8/20 0.67
MET P08581 5/20 0.67
PTK2B Q14289 3/20 0.67
MEN1 O00255 2/20 0.67
CDK2 P24941 2/20 0.67
KMT2A Q03164 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
CCNE1 P24864 1/20 0.67
RECQL P46063 1/20 0.67
PDGFRB P09619 8/20 0.55
SRC P12931 5/20 0.55
LCK P06239 3/20 0.55
ALK Q9UM73 3/20 0.55
EGFR P00533 2/20 0.55
YES1 P07947 2/20 0.55
FLT3 P36888 2/20 0.55
AURKB Q96GD4 2/20 0.55
ABL1 P00519 2/20 0.55
CSF1R P07333 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144626 0.93 KDR (0.66) KDRFGFR1METPTK2BMEN1
SCHEMBL141543 0.93 KDR (0.66) KDRFGFR1METPTK2BMEN1
SCHEMBL145435 0.93 KDR (0.76) KDRFGFR1METPTK2BMEN1
SCHEMBL7125587 0.92 KDR (0.65) KDRFGFR1METPTK2BMEN1
SCHEMBL144867 0.91 KDR (0.64) KDRFGFR1METPTK2BMEN1
SCHEMBL142810 0.91 KDR (0.64) KDRFGFR1METPTK2BMEN1
SCHEMBL143281 0.91 KDR (0.63) KDRFGFR1METPTK2BMEN1
SCHEMBL140987 0.91 KDR (0.63) KDRFGFR1METPTK2BMEN1
SCHEMBL145802 0.90 KDR (0.62) KDRFGFR1METPTK2BMEN1
SCHEMBL143738 0.89 KDR (0.69) KDRFGFR1METPTK2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885MET 310/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885MET 310/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885FGFR1 637/4885MET 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.